The associated specificity and sensitivity were 95.1% and 90.6% in the learning set (175 samples), 94.1% and 91.9% in the validation set (307 samples), respectively.
The accumulation of classical monocytes, which demonstrate a distinct gene expression pattern, is independent of the mutational background. Importantly, this increase disappears in patients who respond to hypomethylating agents. We conclude that an increase in the fraction of classical monocytes over 94.0% of total monocytes is a highly sensitive and specific diagnostic marker that rapidly and accurately distinguishes CMML from confounding diagnoses.
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Introduction
According to the World Health Organization (WHO) classification, the diagnosis of chronic myelomonocytic leukemia (CMML), which is the most frequent myelodysplastic syndrome/ myeloproliferative neoplasm (MDS/MPN), is based on the elevation of peripheral blood monocytes to more than 1.10 9 /L, measured over at least 3 months. 1,2 Bone marrow cell dysplasia, which enforces the diagnosis when present,
is not an absolute requirement. 1 Some patients with reactive monocytosis can fulfill this criterion whereas patients with MDS and a low white blood cell (WBC) count but as much as 80% of monocytes do not.
The Nomenclature Committee of the International Union of Immunological Societies has approved a nomenclature that subdivides monocytes into three subsets. 3 This subdivision was validated by gene expression profiling. [4] [5] [6] Specifically, the expression of CD14, a receptor for bacterial lipopolysaccharides, and CD16, which is the low affinity receptor for IgG (Fcγ-III Classical monocytes constitute the major population of human monocytes (~85%) in healthy conditions. 3 These subsets differ in their chemokine receptor expression and phagocytic activity, 3, 5, 7 i.e. CD14 + /CD16 − monocytes express high levels of CCR2 and low levels of CX3CR1 whereas CD16 + monocytes express high levels of CX3CR1 and low levels of CCR2, [8] [9] [10] Akin to lymphocytes, these subsets may be endowed with specific functions. [4] [5] [6] 11, 12 Here, we demonstrate that an increase in the fraction of classical CD14 Figure 2) were analyzed (Navios, Beckman Coulter). The settings were harmonized between instruments. 15, 16 Flow cytometry standard listmode data were analyzed centrally in a blind fashion using Kaluza software (Beckman Coulter). The monocyte subsets were identified following an exclusion gating strategy ( Supplementary Figures 1-2 ).
Repeatability and reproducibility of the analytic strategy was validated on 20 randomly chosen samples, as described in Supplementary methods. 
Statistical analysis
Principal component analysis was performed using SPADE (Spanning-tree Progression Analysis of Density-normalized Events) algorithm (Cytobank software) 18 .
The non-parametric Kruskal-Wallis test was used to compare distributions between groups. Receiver Operator Characteristic curves (ROC) representing the relationship between sensitivity and specificity were compared with a nonparameteric approach. 
Results

Flow cytometry identification of monocytes subsets
The repartition of monocyte subsets in PBMC from healthy donors was analyzed by flow cytometry. We used an exclusion gating strategy (Supplementary Figure 1) Figure 1A ). 5 Cytological examination showed that each sorted population consisted almost exclusively of monocytes, which were absent from the Differences between groups of the learning cohort but the CMML one were not significant. Figure 4C) , suggesting that the increase in MO1 fraction was not the consequence of a CMML-associated decrease in CD16 expression.
MO1 percentage as a sensitive and specific tool for CMML diagnosis
To further explore whether the increased MO1 monocyte subset could be helpful to diagnose CMML, we performed a ROC analysis using the learning cohort data. The
area under the ROC curve (AUC) was 0.977 (95% Wald confidence limits: 0.96-0.995, Figure 2C ), indicating that the percentage of MO1 monocytes could be used to distinguish CMML from any other situation. The Younden index was defined for all points of the ROC curve in the learning population. The maximum value of the index was used as a criterion for selecting the optimum cut-off point of MO1 percentage to identify CMML. A cut-off value of 94.0% was calculated with a specificity of 95.1%
and a sensitivity of 90.6%. We validated the cut-off value in the independent cohort ( Figure 2D ). In this validation cohort, the specificity and sensitivity of the "MO1 Figure 6) . The specificity and the sensitivity for a MO1 percentage cut-off point of 94.0%, were 100% and 90.4%, respectively. The validation of this cutoff in the patients of the validation cohort with a monocyte count >1.10 9 /L was 94.5%
and 91.7% for specificity and sensitivity, respectively. These data indicate that the MO1 percentage could be used to improve CMML diagnosis in this specific subset of patients with an elevated monocyte count. CMML patients accumulate abnormal classical monocytes.
The MO1 percentage for CMML patients was observed to be independent of the absolute number of circulating monocytes ( Figure 3A) , the gene mutation pattern (Table 1 and Figure 7B) . Moreover, the expression of CD56, CD115, and CD62L was significantly higher at the surface of CMML MO1 cells compared to healthy donors MO1 cells ( Figure 3D ).
Monocyte subset profile is a biomarker of CMML response to demethylating agents
The increase in MO1 monocyte subset remained constantly higher than 94.0% in 21 untreated CMML patients repeatedly analyzed for up to 26 months ( Figure 4A ). We observed also a normalization of monocyte subset repartition, together with a decrease in the monocyte count below 1.10 9 /L, in seven CMML patients who responded to azacytidine therapy ( Figure 4B , exemplified in 4C, and Supplementary Figure 8A ), whereas monocyte repartition remained unchanged in non-responding patients ( Figure 4D ) and a characteristic phenotype re-appeared in a patient who relapsed after initial response ( Figure 4E ). Lastly, in a CMML patient who relapsed on azacytidine therapy, we observed a normalization of monocyte count and MO1 fraction in response to decitabine (Supplementary Figure 8B) . Altogether, these results indicate that the monocyte subset repartition could be used as a biomarker of demethylating agent activity in CMML patients. whereas the specificity and sensitivity of the monocyte count were 95.3% and 62.0%,
respectively. These results demonstrate that the MO1 percentage is a better parameter than the monocyte count to diagnose a CMML at initial workup. In a
multivariate logistic regression model, in which both MO1 percentage and monocyte count were entered, only the MO1 percentage was retained to classify the patients in the CMML group.
Looking in more details to 11 MDS patients with a MO1 fraction higher than 94.0%, all had a fluctuating monocyte count around 1.10 9 /L, precluding the diagnosis of CMML according to the WHO (exemplified in Figure 5B ). These observations suggest that the flow cytometry assay identifies CMML in situations in which the WHO criteria are (still) not fulfilled. Conversely, in a patient classified as CMML-1
according to the WHO that we serially explored over a two-year period ( Figure 5C ), we never detected the characteristic MO1 accumulation and bone-marrow examination revealed a sideroblastic anemia with mutations in SF3B1 and DNMT3A
genes. Further investigation may distinguish a CMML with an unusual phenotype, e.g.
due to a specific background of genetic alterations, from a sideroblastic anemia with monocytosis.
21,22
Discussion
We show that CMML is characterized by an increase in the fraction of classical CD14 + /CD16 -cells (MO1) among circulating monocytes, whatever the genetic background of the disease. This increase can be rapidly identified using a robust multi-parameter flow cytometry assay performed on peripheral blood, and distinguishes CMML from reactive monocytosis and myeloid malignancies with a borderline monocyte count. Importantly, normalization of the monocyte subset repartition could be used as a biomarker of treatment efficacy in this disease.
For
The development and biological significance of monocyte subsets remains a matter of active investigation. 
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Legends Figure 1: Monocyte subsets in peripheral blood mononucleated cells (PBMC).
PBMC from a representative healthy blood donor were explored. A. PBMC were labeled with anti-CD45, -CD24, -CD14, -CD16, -CD56, -CD115, -CD62L, -CD64, -CCR2 and -CX3CR1 antibodies. Monocytes were identified using an exclusion gating strategy (described in Supplementary figure 1 ) and subsets were separated on CD14 The difference between the two curves was highly significant (P<10 -4 , Chi-square). B.
Monocyte subset repartition analysed in two independent samples obtained from 
